Market Survey on Filariasis Treatment Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Filariasis Treatment Market including Drugs, and Vaccine Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
Filariasis Treatment Market Snapshot (2023 to 2033)
The global filariasis treatment market is expected to reach US$ 10.96 Billion in 2023 and is projected to exhibit a CAGR of 10.1% from 2023 to 2033. As a disease of the poor and a sign of underdevelopment, filariasis is more prevalent in Africa and the developing world.
Because cities are growing unplanned and mosquito breeding sites are numerous, the prevalence of infection continues to increase. In spite of its serious economic and social consequences, lymphatic filariasis is one of the most prevalent tropical diseases worldwide. Only 0.6% of Indian cases are caused by Brugia malayi, while 99.4% are caused by Wuchereria bancrofti.
An MDA drive for eliminating filaria was conducted previously in 22 districts in Bihar. Local government health workers and Asha workers distributed the drug to every house in backward villages & small towns. 'National Filaria Prevention Programme' was launched by the Central government on March 23, 2020. Anti-filarial drugs are administered annually in a single dose (Mass Drug Administration - MDA) to prevent new infections and diseases.
Data Points
Key Statistics
Estimated Base Year Value (2022)
US$ 10 Billion
Expected Market Value (2023)
US$ 10.96 Billion
Anticipated Forecast Value (2033)
US$ 28.68 Billion
Projected Growth Rate (2023 to 2033)
10.1% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Filariasis Treatment Market Demand Analysis vs. Forecast 2023 to 2033
The global demand for filariasis treatment is projected to increase at a CAGR of 10.1% during the forecast period between 2023 to 2033, reaching a total of US$ 28.68 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 9.6%.
A parasitic infection called lymphatic filariasis continues to threaten 863 million people in 47 countries in the world and requires preventative chemotherapy to prevent the disease from spreading. A preventive chemotherapy combination of safe medicine combinations effectively eliminated lymphatic filariasis by stopping the spread of infection. In the past decade, the spread of infection has been stopped by more than 8.6 billion treatments cumulatively.
Increasing funding and technological advances are likely to drive the future growth of filariasis treatment. The development of new drugs and vaccines, along with the development of new diagnostic tools, are expected to be key drivers for the development of the filariasis treatment market in the future. As filariasis continues to spread in developing countries, the demand for effective treatments is likely to increase, encouraging governments, private companies, and charitable organizations to invest in research and development.
Which are Some Prominent Drivers of the Filariasis Treatment Market?
Growing Incidence of Filariasis Cases to Drive Market Growth
Growing awareness of filariasis' dangers is fueling the market for filariasis treatments. The disease of filariasis has been neglected in the past, yet it can have serious health consequences, including permanent disabilities. In addition, climate change and increased international travel are contributing to the spread of the disease. Therefore, filariasis treatment has become increasingly popular as people become aware of the need for treatment.
Doxycycline, ivermectin, albendazole, and diethylcarbamazine (DEC) are among the drugs that have been used to treat filariasis recently. A number of newer technologies are being used for diagnosing and treating the disease, including PCR-based tests, ELISA tests, and rapid diagnostic tests. Several advances have been made in recent years in using nanoparticles and biodegradable polymers as vectors for delivering drugs. In addition to improving the pharmacokinetics and pharmacodynamic properties of filarial drugs, these technologies could improve the delivery of the drug. As well as the drug-based approach, a combination of vector-based and drug-based approaches remains as a means of enhancing the efficacy of filarial treatment as well.
Governmental Programme to Expand the Market for Filariasis Treatments
Many governmental programs and funds have been initiated that have been designed to treat diseases in various regions across the globe. The government has been launching a series of programs in order to raise awareness and expand the market for treatments in order to stimulate the growth of the market.
For instance, a resolution WHA50.29 from the World Health Assembly urges member states to eliminate lymphatic filariasis. In 2000, the World Health Organization developed the Global Programme to Eliminate Lymphatic Filariasis (GPELF) in response to this problem. Approximately 925 million people received at least one treatment in at least 68 countries between 2000 and 2020, considerably reducing transmission.
Infection prevalence has been reduced below elimination thresholds in 49% (692 million) of those requiring MDA. According to conservative estimates, the program contributed US$ 24 billion to the economy between 2000 and 2007. According to estimates, the treatments provided until 2015 prevented at least US$ 100.5 billion worth of economic losses expected over the life of the cohorts that received these treatments. Another program Accelerated Plan for Eliminating Lymphatic Filariasis 2018 has been launched by the Ministry of Health and Family Welfare. In Arwal (Bihar), Varanasi (Uttar Pradesh), Simdega (Jharkhand), Nagpur (Maharashtra) & Yadgir (Karnataka), the Triple Drug Therapy (IDA) program was successfully implemented. In December 2019, 11 more districts in Uttar Pradesh implemented IDA.
Find your sweet spots for generating winning opportunities in this market.
What are the Obstacles Associated with Filariasis Treatment?
Treatment at a High Cost Restricts the Growth of the Market
There are several obstacles hindering the market growth, such as expensive treatment of filariasis, lack of awareness of lymphatic filariasis disease, and insufficient treatment options. The tendency of lymphatic filariasis to manifest late symptoms and the lack of treatments available are likely to be some of the factors that will limit the growth of the market during the forecast period.
Moreover, there is no health remuneration policy on the part of the government, and increased costs and medication side effects are also estimated to inhibit the growth of this market. The treatment for filariasis and other parasitic diseases is not widely available in some parts of the world, making it untreatable. Some strains of filariasis are becoming resistant to certain medications, making treatment more difficult. Increasing resistance to certain drugs makes treating filariasis more difficult. Treatment for filariasis can take a long time, even with medication and other treatments. Additionally, treatment will often involve multiple medications that take several months to reach completion or long-term remission.
Region Wise Insights
How is the Asia Pacific Region's Market for Filariasis Treatment Performing?
Healthcare Spending Improving in Asia Pacific Fuels Filariasis Treatment
The Asia Pacific region is projected to grow at a CAGR of 4% during the forecast period, the fastest of all regions. Increased awareness, increasing spending on healthcare, and a rising incidence of filariasis in the region are the main reasons for the growth in this area. In Asia Pacific, demand for lymphatic filariasis treatment is likely to be fuelled by the presence of major manufacturers, early adoption of new products, and a growing number of patients with lymphatic filariasis.
In the Asian Pacific region, a point-of-care approach has grown significantly, resulting in an emerging health and care market. The treatment market worldwide is set to grow with an increasing number of hospitals in India and China. As a result of new projects and the development of new therapies, it is expected that the market for filariasis treatment will grow significantly in the future. For instance, the LSTM Department of Vector Biology recently signed a contract with the All-India Institute of Medical Sciences, Patna, to conduct future research on disease vectors prevalent in Bihar, such as leishmaniasis, filariasis, malaria, dengue, chikungunya, and Japanese encephalitis.
About 40% of the global burden of filariasis is carried by India and 50% of the worldwide population is at risk of infection due to filariasis. As a result of recent drug developments, there are many new drugs being introduced to the market for the treatment of filariasis. For instance, The Bengal government launched a special drive of mass drug administration to eradicate filariasis in five districts such as Purulia, Bankura, Birbhum, Murshidabad, and West Burdwan. The drive was inaugurated at the cultural community hall of the Bolpur municipality.
What is the Projected Growth Rate for the European Filariasis Treatment Market?
European Reimbursement Policies Favor the Demand for Filariasis Treatment
According to the forecast, the European market will account for about 26% of the worldwide market. The increasing prevalence of the disease in the region is one of the factors contributing to this growth in the region. Medications, surgery, and lifestyle changes are used in Europe to treat filariasis.
There are several medications available that are effective at killing parasites and reducing symptoms, including diethylcarbamazine, albendazole, and ivermectin. Physical deformities caused by the infection are frequently corrected by surgery in the event that they are caused by the infection. The risk of infection can also be reduced by wearing long-sleeved clothing, avoiding mosquito bites, and using insect repellents. Public health measures are also capable of helping to reduce the spread of the infection, such as mosquito control and the improvement of sanitation, to continue to help control the spread of the disease.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category Wise Insights
How will the Global Drug Market for Filariasis Treatment Grow?
Innovative Drugs to Grow Market for Filariasis Treatment Market
Drugs are projected to grow at a CAGR of 3% from 2023 to 2033. Throughout the next few years, there is expected to be a boost in industry growth due to the introduction of new technologies and increased public awareness about the drugs used in the market. The drug segment accounted for the largest share of the global filariasis treatment market in 2023. As drugs are increasingly used to treat filariasis and major manufacturers launch products that contain diethylcarbamazine, this segment is expected to dominate the global market.
Moxidectin, a topical gel formulation for the treatment of onchocerciasis and loiasis, was recently approved by the US Food and Drug Administration (FDA). In addition to being convenient for patients, the single-dose formulation is expected to increase the market's growth. There are currently no approved treatments for L1 larvae (microfilariae), and all three of these treatments require repeated application over extended periods of time. Ivermectin (IVM), diethylcarbamazine (DEC), and albendazole (ABZ) are the only treatments that are approved for use. There are concerns regarding the adverse effects of both single and combinatorial treatment options for onchocerciasis, and IVM-resistant strains are emerging. This creates a significant need for compounds with adult-stage selectivity (macrofilaricidal).
Which Application is Expected to Grow Market for Filariasis Treatment Market?
Hospital to be Most Promising Segment for Filariasis Treatment Market
Based on the application, the global market is segmented into hospitals, clinics, and others. Based on forecasts, hospitals will account for 72% of the filariasis treatment market share.
Among the available treatment options for filariasis, hospitals are the most preferred as they provide the most comprehensive and advanced treatment options for this condition. Hospitals have access to the most sophisticated diagnostic and treatment technologies in order to diagnose and treat patients with filariasis accurately.
As well as providing medication, surgery, and counseling for filariasis patients, hospitals may also provide multiple treatment options for the disease. As an additional benefit, hospitals also provide an environment that is safe and hygienic for patients who are receiving treatment there. Furthermore, hospitals may be able to offer patients support groups and other services in order to help them manage their diseases.
The Start-Up Ecosystem: What is the Future of Growth for Start-up?
Start-ups in the field of filariasis include the following:
Medicines Development was founded in 2005 in Australia. The firm focuses on the development of therapies for overcoming river blindness (onchocerciasis) and scabies before the disease becomes epidemic. Onchocerciasis, lymphatic filariasis, and scabies are all treated with the company's lead candidate, moxidectin. This substance is a GABA-receptor agonist and a glutamate-gated channel agonist. A phase III clinical trial has been completed for the candidate.
RTDx was founded in 2017 in, the United States. RTDx designs rapid diagnostic tests and software to diagnose pathogens. In addition to health monitoring, they provide solutions for agriculture monitoring as well. In addition to testing for diseases like Fumonisin, Aflatoxin, Filariasis, Onchocerciasis, and Schistosomiasis, among others, the company also develops rapid lateral flow testing devices. There is also a software product offered by the company that enables the detection of pathogens in agricultural products.
Biocan Diagnostics offers rapid infectious disease diagnostics in a single step. As part of its product line, it offers immunoassays that are designed to detect tropical viruses such as zika virus, dengue, chikungunya, filariasis, leishmaniasis, malaria, CMV, Chagas, leptospira, gonorrhea, herpes, typhoid, H. pylori, rubella, Strep A & B and influenza.
Competitive Landscape
Research and development activities are underway by key players in the global filariasis treatment market in order to launch novel devices and therapeutics for the treatment of filariasis. In order to gain a competitive edge over their counterparts, companies aim to obtain approval for their new products in a timely manner.
An LSTM-led partnership has begun its first human trial of a new drug that targets lymphatic filariasis and onchocerciasis. More than 150 million people worldwide suffer from lymphatic filariasis (LF) and onchocerciasis. In contrast to most parasitic worm drugs, AWZ1066S targets Wolbachia, a bacterial symbiont that is crucial to a parasitic worm's survival. Through the direct involvement of Eisai Corp. Ltd., the progress of the drug candidate through the pipeline has been accelerated. This has resulted in the candidate being ready for the first clinical trial in humans.
The Astellas Global Health Foundation has announced a five-year grant program worth $3.9 million that will provide grants to organizations working to improve the health of the Dominican Republic, Honduras, El Salvador, Guinea Bissau, Senegal, Kenya, and Uganda by improving access to health care, community resilience, and disaster support. Increasing access to health care, building resilient communities, and providing disaster support are just a few of the ways the Foundation's grants will allow it to continue its work in low- and middle-income regions where Astellas has no presence.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 10.96 Billion
Market Value in 2033
US$ 28.68 Billion
Growth Rate
CAGR 10.1%
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Type
Application
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)
Key Countries Profiled
United States
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
China
Japan
South Korea
Singapore
Thailand
Indonesia
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Johnson & Johnson Private Limited
Pfizer Inc.
Elsai Co Ltd
Atra Pharmaceuticals
AbbVie Inc
K.A. Malle Pharmaceuticals
Unimark Remedies
Cipla
Bausch Health
Novartis AG
Customization
Available Upon Request
Key Segments Profiled in the Filariasis Treatment Industry Survey?
By Type:
Drugs
Vaccine
By Application:
Hospitals
Clinics
Others
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)
Frequently Asked Questions
What is the Current Market Valuation?
The market is estimated to secure a valuation of US$ 10.96 billion in 2023.
What is the Growth Potential of the Market?
The growth potential of the market is 10.1% through 2033.
How Big will be the Market Size by 2033?
The global market size is estimated to reach US$ 28.68 billion by 2033.
Who are the Leading Market Players?
Pfizer Inc., Elsai Co. Ltd., and Cipla are the leading market players.
Which is the Top Obstacle in the Market?
Treatment at a high cost restricts the growth of the market.
Table of Content
1. Executive Summary | Filariasis Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. Drug
5.3.2. Vaccine
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Other
6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East & Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Type
8.2.3. By Application
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Type
8.3.3. By Application
8.4. Key Takeaways
9. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Type
9.2.3. By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Application
9.4. Key Takeaways
10. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Type
10.2.3. By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Application
10.4. Key Takeaways
11. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Type
11.2.3. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Application
11.4. Key Takeaways
12. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Type
12.2.3. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Application
12.4. Key Takeaways
13. Key Countries Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Type
13.1.2.2. By Application
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Type
13.2.2.2. By Application
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Type
13.3.2.2. By Application
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Type
13.4.2.2. By Application
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Type
13.5.2.2. By Application
13.6. UK
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Type
13.6.2.2. By Application
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Type
13.7.2.2. By Application
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Type
13.8.2.2. By Application
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Type
13.9.2.2. By Application
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Type
13.10.2.2. By Application
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Type
13.11.2.2. By Application
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Type
13.12.2.2. By Application
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Type
13.13.2.2. By Application
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Type
13.14.2.2. By Application
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Type
13.15.2.2. By Application
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Type
13.16.2.2. By Application
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Type
13.17.2.2. By Application
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Type
13.18.2.2. By Application
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Type
13.19.2.2. By Application
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Type
13.20.2.2. By Application
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Type
14.3.3. By Application
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Johnson & Johnson
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Pfizer
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Eisai Co Ltd
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Atra Pharmaceuticals
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. AbbVie Inc
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. K. A. Malle Pharmaceuticals
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Unimark Remedies
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Cipla
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Bausch Health
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Norvartis AG
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used17. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Million) Forecast by Type, 2018 to 2033
Table 3: Global Value (US$ Million) Forecast by Application, 2018 to 2033
Table 4: North America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Value (US$ Million) Forecast by Type, 2018 to 2033
Table 6: North America Value (US$ Million) Forecast by Application, 2018 to 2033
Table 7: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Value (US$ Million) Forecast by Type, 2018 to 2033
Table 9: Latin America Value (US$ Million) Forecast by Application, 2018 to 2033
Table 10: Europe Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Value (US$ Million) Forecast by Type, 2018 to 2033
Table 12: Europe Value (US$ Million) Forecast by Application, 2018 to 2033
Table 13: Asia Pacific Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Value (US$ Million) Forecast by Type, 2018 to 2033
Table 15: Asia Pacific Value (US$ Million) Forecast by Application, 2018 to 2033
Table 16: MEA Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: MEA Value (US$ Million) Forecast by Type, 2018 to 2033
Table 18: MEA Value (US$ Million) Forecast by Application, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Value (US$ Million) by Type, 2023 to 2033
Figure 2: Global Value (US$ Million) by Application, 2023 to 2033
Figure 3: Global Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 8: Global Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 9: Global Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 10: Global Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 11: Global Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 12: Global Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 13: Global Attractiveness by Type, 2023 to 2033
Figure 14: Global Attractiveness by Application, 2023 to 2033
Figure 15: Global Attractiveness by Region, 2023 to 2033
Figure 16: North America Value (US$ Million) by Type, 2023 to 2033
Figure 17: North America Value (US$ Million) by Application, 2023 to 2033
Figure 18: North America Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 23: North America Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 24: North America Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 25: North America Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 26: North America Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 27: North America Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 28: North America Attractiveness by Type, 2023 to 2033
Figure 29: North America Attractiveness by Application, 2023 to 2033
Figure 30: North America Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Value (US$ Million) by Type, 2023 to 2033
Figure 32: Latin America Value (US$ Million) by Application, 2023 to 2033
Figure 33: Latin America Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 38: Latin America Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 39: Latin America Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 40: Latin America Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 41: Latin America Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 42: Latin America Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 43: Latin America Attractiveness by Type, 2023 to 2033
Figure 44: Latin America Attractiveness by Application, 2023 to 2033
Figure 45: Latin America Attractiveness by Country, 2023 to 2033
Figure 46: Europe Value (US$ Million) by Type, 2023 to 2033
Figure 47: Europe Value (US$ Million) by Application, 2023 to 2033
Figure 48: Europe Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 53: Europe Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 54: Europe Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 55: Europe Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 56: Europe Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 57: Europe Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 58: Europe Attractiveness by Type, 2023 to 2033
Figure 59: Europe Attractiveness by Application, 2023 to 2033
Figure 60: Europe Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Value (US$ Million) by Type, 2023 to 2033
Figure 62: Asia Pacific Value (US$ Million) by Application, 2023 to 2033
Figure 63: Asia Pacific Value (US$ Million) by Country, 2023 to 2033
Figure 64: Asia Pacific Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 68: Asia Pacific Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 69: Asia Pacific Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 70: Asia Pacific Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 71: Asia Pacific Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 72: Asia Pacific Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 73: Asia Pacific Attractiveness by Type, 2023 to 2033
Figure 74: Asia Pacific Attractiveness by Application, 2023 to 2033
Figure 75: Asia Pacific Attractiveness by Country, 2023 to 2033
Figure 76: MEA Value (US$ Million) by Type, 2023 to 2033
Figure 77: MEA Value (US$ Million) by Application, 2023 to 2033
Figure 78: MEA Value (US$ Million) by Country, 2023 to 2033
Figure 79: MEA Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 83: MEA Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 84: MEA Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 85: MEA Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 86: MEA Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 87: MEA Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 88: MEA Attractiveness by Type, 2023 to 2033
Figure 89: MEA Attractiveness by Application, 2023 to 2033
Figure 90: MEA Attractiveness by Country, 2023 to 2033
